List view / Grid view
25 September 2015 | By Victoria White
Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists...
25 September 2015 | By Victoria White
TLR agonists are promising agents that activate innate immune cells and enhance the visibility of cancer tumours...
25 September 2015 | By Victoria White
Researchers discovered that FAK inhibition can modulate the balance of immune cells in a tumour enabling an immune response to destroy the cancer cells...
25 September 2015 | By Victoria White
When eCD4-lg was tested in animal models, the results were so powerful and effective that they suggested the compound’s potential to serve the role of an alternative HIV/AIDS vaccine...
25 September 2015 | By Victoria White
The team of researchers will comprehensively study human proteomes with the aim of turning the vast amount of molecular information into designs for new reagents, equipment, workflows, assays and software...
24 September 2015 | By Victoria White
Regeneron will provide the ETI with access to VelocImmune technology to generate antibodies against targets of interest and explore potential therapeutic applications for human disease...
24 September 2015 | By Victoria White
Disregulation of MALT1 is associated with some subsets of lymphoma suggesting that MALT1 could be a promising drug target for these types of cancer...
24 September 2015 | By Victoria White
Deubiquitylating enzymes (DUBs) are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs...
23 September 2015 | By Victoria White
The new smart research robot, developed at Uppsala University, accelerates research on cancer treatments by finding optimal treatment combinations...
23 September 2015 | By Victoria White
The collaboration will develop a sensitive, minimally invasive Tau diagnostic assay for early Alzheimer’s disease by applying Nestlé’s multiplexed ultrasensitive antibody technology platform...
23 September 2015 | By Victoria White
C4XD expects to progress its type 2 diabetes and inflammation programmes into in vivo proof-of-principle testing in the next few months...
23 September 2015 | By Victoria White
Inquiro gathers all unstructured data – from R&D to preclinical data – and allows researchers to organise and interconnect such data, facilitating large-scale collaborations among geographically distant research teams...
23 September 2015 | By Victoria White
NanoBio’s intranasal nanoemulsion adjuvanted genital herpes vaccine demonstrated efficacy in studies conducted in prophylactic and therapeutic models...
22 September 2015 | By Victoria White
This work builds on previous successful collaborations between Zedira and Cardiff University in the arena of the autoantibody response in gluten-related disorders...
22 September 2015 | By Victoria White
The companies are validating the druggability of two kinase targets in a specific genetic context and have generated multiple novel chemical series against these targets...
